Paracetamol + Codeine tablets manufacturers & suppliers

Paracetamol + Codeine Tablets

Form: Tablets

Strength: 300 mg paracetamol + 30 mg codeine; 300 mg + 60 mg

Reference Brands: Tylenol with Codeine(US)

Category: Analgesic

Paracetamol + Codeine tablets are approved in the EU and US for moderate pain relief. In the US, brands like Tylenol with Codeine are regulated by the DEA as Schedule II controlled substances, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the EU, regulations vary by country, with strict control measures for codeine-containing products. Both regions require detailed dossiers, clinical data, and pharmacovigilance plans for initial approval and ongoing safety. To ensure compliance, navigate complex regulations, and facilitate market access, visit PharmaTradz. We support seamless registration and compliance for paracetamol + codeine formulations, ensuring adherence to European and American standards for safe, effective pain management.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Paracetamol (Acetaminophen) Injection

Strength: 1000 mg/100 mL (10 mg/mL)

Form: Injectable solution

Reference Brands: Ofirmev

View Details
Dexketoprofen + Tramadol Tablets

Strength: 25 mg dexketoprofen + 37.5 mg tramadol

Form: Tablets

Reference Brands: Enantyum(EU)

View Details
Aceclofenac + Paracetamol Tablets

Strength: 100 mg Aceclofenac + 325 mg Paracetamol

Form: Tablets

Reference Brands: Generic formulations marketed under different names

View Details
Tramadol + Paracetamol Tablets

Strength: 37.5 mg tramadol + 325 mg paracetamol; 75 mg + 650 mg

Form: Oral Tablets

Reference Brands: Ultracet(US); Tramacet(EU)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.